Various gene editing methods (TALENs, Zinc-finger nucleases, and CRISPR/Cas9) have been used with allogeneic transplants to reduce the risk for GvHD and enhance T cell persistence . Due to the manufacturing drawbacks of autoCAR-T cells, allogeneic cells should continue to be developed as a cheaper alternative. Gene editing of allogeneic T cells should be explored, especially to minimize life-threatening risks like GvHD and short persistence, which could lead to relapse.